Show all News

We are working to develop our technology and commercialise MSC-based pharmaceuticals – find out more about our day-to-day work.

NCBR focuses on modern medicine

In the years to come, we are going to see a crop of biotechnology and other projects with global potential. Breakthrough innovations will not happen by accident but will rather result from a pre-programmed process, supported, among others, by the National Centre for Research and Development under the “Fast Track” scheme. Indeed, Bioceltix, a start-up from Wrocław is one of the companies that develop its projects under the latter programme. The company’ aim is to market veterinary biological drugs based on mesenchymal stem cells (MSC). More here.

Wrote about us

On 02/03/2021 there was an investor chat with our participation. We invite you to watch the chat here: https://www.pb.pl/czat-inwestorski-ze-spolka-bioceltix-akcja-inwestor-1109458

Article

Puls Biznesu

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...

Article

Forbes- Incredibles

Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...

Article

Investors’ Zone

According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...

Article

Portal Wrocław

Gazeta Wrocławska wrote about us: “Bioceltix is ​​working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...

Article